Four biotech companies and Matthew Roden led SPAC in pricing the IPO

four other biotech companies and SPAC, led by Bristol Myers Squibb veterinarian Matthew Roden, priced their IPOs, ending another busy week on Wall Street.MPM's blank checking companies Praxis Precision Pharmaceuticals, Tarsus Pharmaceuticals, Aligos Therapeutics, Kiromic BioPharma andTurmeric Acquisition together raised $528 million in an initial public offering., Praxis Precision Medicines came out on top with $100 million and quickly earned $110 million in July. On Thursday, it raised $190m through a major IPO, almost double its initial target. PRAX, a Cambridge, Massachusetts-based biotech company, issued 10m shares at $19 a share, up from its initial offering price of $7.4m of $17 to $18 a share.prices of between $70 million and $80 million for the clinical development of PRAX-114, the company's main central nervous system candidate drug. The money will be used to fund future Phase II/III trials in severe depression and to complete the ongoing Phase IIa. An additional $300,000 to $40 million will be spent on the ongoing PRAX-944 Phase IIa study in basic tremors. And by completing the $200,000 to $30 million PRAX-562 trial, PRAX-562 is a candidate for Praxis' treatment of rare central nervous system disorders such as severe childhood epilepsy and adult headaches.Praxis has burned more than $104 million since its launch, according to S-1/A. Blackstone owns 23.1 per cent, followed by Eventide 9.4 per cent, Vida Ventures 7.3 per cent and Novo Holdings 6.6 per cent.S-1/A said: "We hope to obtain a number of important clinical trial results from our three clinical phase product candidates by the end of 2021 and expect to launch a new clinical development program in 2021. Tarsus Pharmaceuticals, the company's , also slightly above its original target, raising $88m by issuing 5.5m shares at $16 a share. Irvine, California-based biotech company TARS filed for an IPO on September 25 for $86 million, according to SEC filings. The company raised its offer by 575,000 shares.of the proceeds (about $65 million) will be injected into TP-03, the company's leading ophthalmology candidate. The drug is currently in phase IIb/III trials of peristaltic blepharitis, a disease characterized by inflammation of the eyes and caused by aphid infested. Tarsus is expected to conduct phase III trials in 2021. The remaining funds may be allocated to the biotech company's other candidate products, TP-04 and TP-05, which are scheduled to enter Phase I/II trials for rosacea and Lyme disease in 2021, respectively.Tarsus has spent a total of $11.2 million since its inception in 2017. Vivo Capital owns 15.77 per cent, while CEO Bobak Azamian has 9.7 per cent.Aligos Therapeutics ALGS filed for a $100 million IPO in September to develop its chronic hepatitis B (CHB) and NASH treatments. Now, the San Francisco, California-based biotech company has earned $150m by issuing 10m shares at $15 a share, the mid-point of the $14-$16 range.about $40 to $43 million will be spent on the company's Phase I STOPS candidate, ALG-010133, an acronym for oligonucleotide polymers that inhibit the transport of S antigens. An additional $35 million to $38 million will be spent on the upcoming first phase of the CAM (Shell Assembly Modulator) candidate ALG-000184 trial. NASH THR-b candidate ALG-055009 will receive $12 to $14 million. Aligos allocated $12 to $15 million and $12 to $14 million, respectively, to its CHB candidates, ALG-020572 and ALG-125097.the two-year-old biotech company has spent $107 million, according to its S-1/A. Lawrence Blatt, the company's chief executive, was Janssen's head of infectious diseases and owns 6.2 per cent. Roche Finance, Versant Ventures and Baker Brothers Advisors own 8.4 per cent, respectively, followed by Vivo at 8.1 per cent, Novo at 6.6 per cent and Wellington Management at 5.2 per cent., a blank cheque company founded by MPM Capital, eventually cut its offer from 10m to 8.5m. SPAC raised $85 million at $10 a share.TMPMU is co-owned by chief executive Luke Evnin and his chairman Roden, who co-founded MPM Capital in 1997.the two men, together with the rest of the company, now have two years to choose a private company, bring turmeric to NASDAQ and inherit the investment.SPAC's S-1/A states: "We have not selected any business consolidation objectives, nor have we, nor have anyone discussed substantively, directly or indirectly, on our behalf with any business consolidation objectives."BioPharma KRBP on Friday set its share price at $12 a share, the low end of its $12 to $14 range. The Houston, Texas-based biotech company raised $15 million by issuing 1.3 million shares. The company is using AI to develop cancer therapies and says the IPO funds will push its Alexis subshaped mesothylpocytin (for EOC) and PD-1 candidates into the clinic.56 biotech companies had filed for IPOs this year, up from Brad Loncar's 47 last year. SQZ Biotech and Lux Health Health Team, a SPAC made up of Lux Capital, both filed for public listing on Monday. SQZ is proposing to raise $75 million to develop its cell therapy, while Lux wants to raise $300 million. On Tuesday, Kodiak's shares were priced at $15 a share, net income of $83 million.
（cyy123.com）